New Drug Design and Therapeutic Development for Heart Failure
Cardiovascular diseases (CVDs) are the number one cause of death globally according to the World Health Organization. They account for approximately 30% of all global deaths and incur great medical costs. Chronic or congestive heart failure (CHF) remains the most prevalent diagnosis requiring hospitalization. Current treatments for heart failure patients aim to improve quality of life by treating signs and symptoms but patient outcomes remain poor. Discovery and development of new heart failure therapies is an active research area seeking to address this unmet medical need. In this chapter, we review (1) new drugs in the clinic for existing targets and (2) new targets that are currently being evaluated in the clinic. Topics include new mechanistic and clinical research of the renin–angiotensin–aldosterone pathway, inotropes and treatments for dyslipidemia. In addition, novel mechanisms for heart failure including drugs targeting mitochondrial function, inflammatory pathways as well as kinase inhibitors are discussed.